RÉSUMÉ
OBJECTIVE: To explore the efficacy and safety of combination therapy with methotrexate (MTX) plus hydroxychloroquine (HCQ) vs. MTX monotherapy in patients with rheumatoid arthritis (RA). METHODS: Sixty patients without prior RA treatments were randomly allocated in a 1:1 ratio to two groups: one receiving MTX plus HCQ, and the other receiving MTX monotherapy. We conducted a comparative analysis before and after the 12-week trial, evaluating the visual analogue scale (VAS), the disease activity score in 28 joints (DAS), serum inflammatory factor (including serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-α), as well as the outcome of the World Health Organization Quality of Life Brief Version questionnaire (WHOQOL-BREF) and the treatment-emergent adverse events (TEAEs) for all the participants in the study. RESULTS: At the 12th week of the trial, a more remarkable decrease in pain score (VAS), disease activity score (DAS), and serum inflammatory factor levels could be noticed in individuals on the combination therapy. The quality of life score was as well found to be higher in the MTX + HCQ group than the MTX monotherapy group. The incidence of adverse reactions in the MTX + HCQ and the MTX monotherapy groups were 10.00% and 6.67%, respectively. However, no statistical significance could be observed (p > .05). CONCLUSION: In our study, both the MTX + HCQ combination therapy and MTX monotherapy demonstrated improvements in symptoms, conditions and quality of life for patients with RA. Notably, the combination therapy could achieve better outcomes across all indices compared to MTX monotherapy, highlighting its potential as the optimal first-line treatment for RA. © 2024 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Sujet(s)
Antirhumatismaux , Polyarthrite rhumatoïde , Association de médicaments , Hydroxychloroquine , Méthotrexate , Qualité de vie , Humains , Méthotrexate/effets indésirables , Méthotrexate/administration et posologie , Méthotrexate/usage thérapeutique , Hydroxychloroquine/effets indésirables , Hydroxychloroquine/administration et posologie , Hydroxychloroquine/usage thérapeutique , Polyarthrite rhumatoïde/traitement médicamenteux , Polyarthrite rhumatoïde/diagnostic , Polyarthrite rhumatoïde/sang , Femelle , Antirhumatismaux/effets indésirables , Antirhumatismaux/administration et posologie , Antirhumatismaux/usage thérapeutique , Mâle , Résultat thérapeutique , Adulte d'âge moyen , Adulte , Facteurs temps , Mesure de la douleur , Marqueurs biologiques/sang , Sujet âgé , Médiateurs de l'inflammation/sangRÉSUMÉ
PURPOSE: To assess structural (optical coherence tomography, fundus autofluorescence) and functional (contrast sensitivity and visual field) test results which were used for detecting early retinal changes in patients using oral hydroxychloroquine. METHODS: Patients using oral hydroxychloroquine for at least one year were divided into two groups according to the duration of drug use. Groups 1 and 2 consisted of patients with drug use for more than 5 years and 1-5 years, respectively. The drug-using groups were compared with the control group. The mean retinal nerve fiber layer (RNFL), central macular thickness (CMT), ganglion cell-inner plexiform layer (GC-IPL), static 10-2 visual field, fundus autofluorescence (FAF) imaging, and contrast sensitivity tests were performed and statistically compared between groups. RESULTS: Median and temporal quadrant RNFL thicknesses were found to be statistically significantly lower in the drug groups. In the drug groups, the GC-IPL sectoral and mean thicknesses were found to be statistically lower in all quadrants. Central macular thickness was also found to be similar in all three groups. There was no significant difference between the groups in visual field parameters. Macular FAF images were significantly higher in the drug users, but there was no significant difference between the three groups in foveal FAF images. Contrast sensitivity measurements were significantly lower in the drug groups than in the control group at all spatial frequencies except 6 and 18 cycles/degree. CONCLUSIONS: The combined use of structural and functional tests in patients using hydroxychloroquine provides useful information in detecting early retinal changes.
Sujet(s)
Antirhumatismaux , Sensibilité au contraste , Diagnostic précoce , Angiographie fluorescéinique , Hydroxychloroquine , Macula , Rétinopathies , Cellules ganglionnaires rétiniennes , Tomographie par cohérence optique , Champs visuels , Humains , Hydroxychloroquine/effets indésirables , Tomographie par cohérence optique/méthodes , Femelle , Mâle , Champs visuels/physiologie , Champs visuels/effets des médicaments et des substances chimiques , Adulte d'âge moyen , Antirhumatismaux/effets indésirables , Rétinopathies/induit chimiquement , Rétinopathies/diagnostic , Macula/effets des médicaments et des substances chimiques , Macula/anatomopathologie , Macula/imagerie diagnostique , Cellules ganglionnaires rétiniennes/anatomopathologie , Cellules ganglionnaires rétiniennes/effets des médicaments et des substances chimiques , Sensibilité au contraste/physiologie , Sensibilité au contraste/effets des médicaments et des substances chimiques , Angiographie fluorescéinique/méthodes , Adulte , Neurofibres/anatomopathologie , Neurofibres/effets des médicaments et des substances chimiques , Acuité visuelle , Tests du champ visuel/méthodes , Sujet âgéSujet(s)
Troubles du rythme cardiaque , Maladies auto-immunes , Chloroquine , Hydroxychloroquine , Humains , Hydroxychloroquine/effets indésirables , Hydroxychloroquine/usage thérapeutique , Chloroquine/effets indésirables , Chloroquine/usage thérapeutique , Maladies auto-immunes/traitement médicamenteux , Maladies auto-immunes/épidémiologie , Troubles du rythme cardiaque/induit chimiquement , Troubles du rythme cardiaque/physiopathologie , Facteurs de risque , Appréciation des risques , Antirhumatismaux/effets indésirables , Antirhumatismaux/usage thérapeutique , Rythme cardiaque/effets des médicaments et des substances chimiquesRÉSUMÉ
Amidst the COVID-19 pandemic, hydroxychloroquine (HCQ) was widely administered despite limited data on its safety and efficacy. This study assesses the acute and chronic impacts of HCQ on electrocardiography (ECG) parameters alongside the effects of azithromycin and levofloxacin coadministration in patients with COVID-19. A comprehensive analysis was conducted on 109 COVID-19 patients receiving HCQ, with or without Azithromycin and/or Levofloxacin, and 51 long-term HCQ-treated Sjogren's syndrome (SS) patients. ECG parameters, including QTc interval, were meticulously evaluated against a control group of 109 COVID-19 patients without HCQ treatment. HCQ monotherapy, in combination with Levofloxacin, significantly prolonged the QTc interval in COVID-19 patients compared to controls. Notably, the combination of HCQ and Azithromycin demonstrated a mitigated impact on QTc prolongation. Long-term HCQ use in SS patients did not significantly affect QTc intervals, illustrating a distinct safety profile from short-term use in COVID-19 treatment. HCQ's impact on QTc prolongation is influenced by therapeutic context, coadministered drugs, and patient demographics. The findings underscore the necessity of cautious HCQ use, particularly in acute settings like COVID-19, where monitoring and consideration of drug interactions and patient-specific factors are critical.
Sujet(s)
Azithromycine , Traitements médicamenteux de la COVID-19 , Électrocardiographie , Hydroxychloroquine , Syndrome du QT long , Humains , Hydroxychloroquine/effets indésirables , Hydroxychloroquine/usage thérapeutique , Hydroxychloroquine/administration et posologie , Électrocardiographie/effets des médicaments et des substances chimiques , Femelle , Mâle , Adulte d'âge moyen , Azithromycine/usage thérapeutique , Azithromycine/effets indésirables , Azithromycine/administration et posologie , Syndrome du QT long/induit chimiquement , Sujet âgé , Syndrome de Gougerot-Sjögren/traitement médicamenteux , Association de médicaments , Lévofloxacine/usage thérapeutique , Lévofloxacine/administration et posologie , Lévofloxacine/effets indésirables , Adulte , SARS-CoV-2 , COVID-19RÉSUMÉ
Importance: Systemic lupus erythematosus (SLE) predisposes individuals to early cardiovascular (CV) events. While hydroxychloroquine is thought to mitigate CV risk factors, its protective role against CV events, particularly arterial ones, remains to be confirmed. Objective: To evaluate the association between hydroxychloroquine and the risk of myocardial infarction (MI), stroke, and other thromboembolic events (OTEs) in patients with SLE. Design, Setting, and Participants: This cohort study using a nested case-control design was conducted within the National French Healthcare Database (SNDS), which represents 99% of the French population, from 2010 to 2020. Participants were the cohort of all patients with SLE recorded in the SNDS. Patients with SLE experiencing CV events during the study period were the case group; those without CV events were controls. The analysis period was from February 2022 to September 2023. Exposures: Hydroxychloroquine use within 365 days prior to the index date, defined as current (within 90 days), remote (91-365 days), or no exposure within the previous 365 days. Main Outcomes and Measures: Outcomes of interest were MI, stroke, and OTE, analyzed individually and as a composite outcome (primary analysis). Controls were matched to patients with CV events by age, sex, time since SLE onset and entry into the SNDS database, index date, prior antithrombotic and CV medication, chronic kidney disease, and hospitalization. Multivariable conditional logistic regression was performed using hydroxychloroquine exposure as the main independent variable. Results: The SLE cohort included 52â¯883 patients (mean [SD] age, 44.23 [16.09] years; 45â¯255 [86.6%] female; mean [SD] follow-up, 9.01 [2.51] years), including 1981 patients with eligible CV events and 16â¯892 matched control patients. There were 669 MI events, 916 stroke events, and 696 OTEs in the individual outcome studies. For current exposure to hydroxychloroquine, the adjusted odds were lower for composite CV events (odds ratio [OR], 0.63; 95% CI, 0.57-0.69) as well as for MI (OR, 0.72; 95% CI, 0.60-0.85), stroke (OR, 0.69; 95% CI, 0.60-0.81), and OTEs (OR, 0.58; 95% CI, 0.49-0.69) individually compared with no hydroxychloroquine exposure within 365 days. Conclusions and Relevance: In this nationwide cohort study of patients with SLE, a protective association was found between the current use of hydroxychloroquine and the occurrence of CV events, but not between remote use of hydroxychloroquine and CV outcomes, highlighting the value of continuous hydroxychloroquine treatment in patients with SLE.
Sujet(s)
Antirhumatismaux , Maladies cardiovasculaires , Hydroxychloroquine , Lupus érythémateux disséminé , Humains , Hydroxychloroquine/usage thérapeutique , Hydroxychloroquine/effets indésirables , Lupus érythémateux disséminé/traitement médicamenteux , Lupus érythémateux disséminé/complications , Femelle , Mâle , Adulte d'âge moyen , Études cas-témoins , Adulte , Antirhumatismaux/usage thérapeutique , Antirhumatismaux/effets indésirables , Maladies cardiovasculaires/épidémiologie , Infarctus du myocarde/épidémiologie , Infarctus du myocarde/induit chimiquement , Accident vasculaire cérébral/épidémiologie , Accident vasculaire cérébral/prévention et contrôle , Études de cohortes , France/épidémiologie , Thromboembolie/épidémiologie , Thromboembolie/prévention et contrôle , Facteurs de risque , Sujet âgéRÉSUMÉ
AIM: Patients with rheumatoid arthritis (RA) are at a higher risk of osteoporotic fractures. Studies have shown that patients with Sjogren's syndrome (SS) and systemic lupus erythematosus (SLE) experienced an increase in bone mineral density (BMD) after receiving hydroxychloroquine (HCQ) treatment, indicating a potential protective effect against osteoporosis. Therefore, this study is to examine the relationship between HCQ usage and the risk of osteoporosis in patients diagnosed with RA. METHODS: The retrospective cohort study used data from Taiwan's National Health Insurance Research Database (NHIRD) covering the period from January 2010 to December 2018, which included 14 050 newly diagnosed RA patients, subsequently divided into two groups: HCQ users and non-users. Propensity score matching (PSM) based on sex, age, urbanization, insured unit type, insured area, and comorbidities was conducted to match the groups. The primary outcome assessed was the evaluation of the risk of osteoporosis by employing a multivariable Cox proportional hazard regression model to calculate the adjusted hazard ratio (aHR). RESULTS: After PSM, a total of 6408 RA patients were included in the analysis (3204 HCQ users and 3204 non-users). There was no significantly higher risk of osteoporosis in HCQ users compared with non-users, aHR = 0.99 (95% CI: 0.82-1.196). Additionally, different durations of HCQ usage demonstrated a neutral effect on the risk of osteoporosis [HCQ <90 days, aHR = 0.88 (95% CI: 0.585-1.324); HCQ 90-180 days, aHR = 0.941 (95% CI: 0.625-1.418); HCQ >180 days, aHR = 1.019 (95% CI: 0.832-1.249)]. CONCLUSIONS: The study indicates that there is no significant association between the use of HCQ and the risk of osteoporosis in patients with RA.
Sujet(s)
Antirhumatismaux , Polyarthrite rhumatoïde , Bases de données factuelles , Hydroxychloroquine , Ostéoporose , Humains , Polyarthrite rhumatoïde/traitement médicamenteux , Polyarthrite rhumatoïde/épidémiologie , Polyarthrite rhumatoïde/diagnostic , Hydroxychloroquine/effets indésirables , Hydroxychloroquine/usage thérapeutique , Études rétrospectives , Ostéoporose/épidémiologie , Ostéoporose/induit chimiquement , Ostéoporose/diagnostic , Femelle , Mâle , Adulte d'âge moyen , Antirhumatismaux/effets indésirables , Taïwan/épidémiologie , Facteurs de risque , Adulte , Sujet âgé , Appréciation des risques , Densité osseuse/effets des médicaments et des substances chimiques , Résultat thérapeutique , Facteurs temps , Facteurs de protectionSujet(s)
Chloroquine , Hydroxychloroquine , Rétinopathies , Tomographie par cohérence optique , Humains , Hydroxychloroquine/effets indésirables , Chloroquine/effets indésirables , Rétinopathies/induit chimiquement , Rétinopathies/diagnostic , Hongrie , Antirhumatismaux/effets indésirables , Électrorétinographie , Dégénérescence maculaire/traitement médicamenteux , Dégénérescence maculaire/diagnostic , Dégénérescence maculaire/induit chimiquement , Guides de bonnes pratiques cliniques comme sujetRÉSUMÉ
Background and Objectives: The coronavirus disease of 2019 (COVID-19) pandemic has posed a serious threat to humanity and is considered a global health emergency. Antimalarial drugs (ADs) have been used in the treatment of immuno-inflammatory arthritis (IIA) and coronavirus infection (COVID-19). The aim of this review is to analyze the current knowledge about the immunomodulatory and antiviral mechanisms of action, characteristics of use, and side effects of antimalarial drugs. Material and Methods: A literature search was carried out using PubMed, MEDLINE, SCOPUS, and Google Scholar databases. The inclusion criteria were the results of randomized and cohort studies, meta-analyses, systematic reviews, and original full-text manuscripts in the English language containing statistically confirmed conclusions. The exclusion criteria were summary reports, newspaper articles, and personal messages. Qualitative methods were used for theoretical knowledge on antimalarial drug usage in AIRDs and SARS-CoV-2 such as a summarization of the literature and a comparison of the treatment methods. Results: The ADs were considered a "candidate" for the therapy of a new coronavirus infection due to mechanisms of antiviral activity, such as interactions with endocytic pathways, the prevention of glycosylation of the ACE2 receptors, blocking sialic acid receptors, and reducing the manifestations of cytokine storms. The majority of clinical trials suggest no role of antimalarial drugs in COVID-19 treatment or prevention. These circumstances do not allow for their use in the treatment and prevention of COVID-19. Conclusions: The mechanisms of hydroxychloroquine are related to potential cardiotoxic manifestations and demonstrate potential adverse effects when used for COVID-19. Furthermore, the need for high doses in the treatment of viral infections increases the likelihood of gastrointestinal side effects, the prolongation of QT, and retinopathy. Large randomized clinical trials (RCTs) have refuted the fact that there is a positive effect on the course and results of COVID-19.
Sujet(s)
Antipaludiques , Traitements médicamenteux de la COVID-19 , Rhumatismes , SARS-CoV-2 , Humains , Antipaludiques/usage thérapeutique , Antipaludiques/effets indésirables , Rhumatismes/traitement médicamenteux , Rhumatismes/complications , COVID-19 , Antiviraux/usage thérapeutique , Antiviraux/effets indésirables , Hydroxychloroquine/usage thérapeutique , Hydroxychloroquine/effets indésirablesSujet(s)
Antirhumatismaux , Hydroxychloroquine , Lupus érythémateux disséminé , Rétinopathies , Hydroxychloroquine/effets indésirables , Hydroxychloroquine/usage thérapeutique , Humains , Rétinopathies/induit chimiquement , Lupus érythémateux disséminé/traitement médicamenteux , Antirhumatismaux/effets indésirablesRÉSUMÉ
Background and Objective: Hydroxychloroquine sulfate (HCQ) is a lysosomotropic agent administered in systemic lupus erythematosus and rheumatoid arthritis that has fewer toxic effects than chloroquine. However, HCQ may still be responsible for retinal toxicity. In this study, we observed structural changes in the retinas of experimental rats after prolonged exposure to HCQ. Matherials and Methods: We investigated several aspects regarding retinal changes, at both the histopathological and ultrastructural levels. We used 96 male albino Wistar rats distributed into four equal groups (n = 24 per group): the first three groups were treated with different doses of HCQ (50, 100, and 200 mg/kg HCQ, injected intraperitoneally in a single dose daily), and the last group (the control group, n = 24) was treated with saline solution administered in the same way (0.4 mL of saline solution). The treated groups received HCQ daily for 4 months, and every month, six animals from each group were sacrificed to assess retinal changes. The eyes were examined via optical (OM) and electronic microscopy (EM). Statistical analysis was deployed, and results regarding retinal morpho-photometry were acquired. Results: We observed structural retinal changes in both high and low doses of HCQ; while high doses determined a significant thinning of the retina, lower doses caused retinal thickening. Morphological retinal changes upon exposure to HCQ are believed to be caused by accumulated HCQ in lysosomes found in retinal ganglion cells and in the inner nuclear and photoreceptor cell layers. Such changes were most evident in the group receiving HCQ intraperitoneally in doses of 100 mg/kg for a longer period (4 months). Conclusions: The present study highlights histopathological and ultrastructural retinal changes induced by chronic HCQ administration, which were strongly connected to the dosage and period of exposure.
Sujet(s)
Hydroxychloroquine , Rat Wistar , Rétine , Hydroxychloroquine/usage thérapeutique , Hydroxychloroquine/pharmacologie , Hydroxychloroquine/effets indésirables , Animaux , Rats , Rétine/effets des médicaments et des substances chimiques , Rétine/ultrastructure , Rétine/anatomopathologie , Mâle , Antirhumatismaux/usage thérapeutique , Antirhumatismaux/pharmacologieRÉSUMÉ
PURPOSE: To assess the quality of hydroxychloroquine (HCQ)-induced retinopathy screening at a Canadian tertiary center, we concentrate on risk factor documentation within the electronic health record, in accordance with the 2016 AAO guidelines. METHODS: We performed a retrospective quality assessment study based on chart review of patients who underwent screening for HCQ-induced retinopathy at the Centre Hospitalier de l'Université de Montréal (CHUM) from 2016 to 2019. We evaluated four key risk factors for HCQ-induced retinopathy: daily dose, duration of use, renal disease, and tamoxifen use, using a three-tier grading system (ideal, adequate, inadequate) for documentation assessment. Pareto and root cause analyses were conducted to identify potential improvement solutions. RESULTS: Documentation quality varied in our study: daily dosage was 33% ideal, 31% appropriate, and 36% inappropriate. Duration of use documentation was 75% ideal, 2% adequate, and 24% inadequate. Renal disease documentation was only 6% ideal, with 62% adequate and 32% of charts lacking any past medical history. Among women's charts, tamoxifen use wasn't documented at all, with 65% adequately documenting medication lists. Pareto analysis indicated that improving renal disease and tamoxifen documentation could reduce 64% of non-ideal records, and enhancing daily dose documentation could decrease this by up to 90%. CONCLUSION: Accurate documentation of key risk factors is critical for HCQ-induced retinopathy screening, impacting both exam initiation and frequency. Our study identifies potential improvements in the screening process at the hospital, referring physician, and ophthalmologist levels. Implementing integrated pathways could enhance patient experience and screening effectiveness.
Sujet(s)
Antirhumatismaux , Hôpitaux d'enseignement , Hydroxychloroquine , Rétinopathies , Humains , Hydroxychloroquine/effets indésirables , Hydroxychloroquine/administration et posologie , Études rétrospectives , Femelle , Rétinopathies/induit chimiquement , Rétinopathies/diagnostic , Mâle , Adulte d'âge moyen , Antirhumatismaux/effets indésirables , Antirhumatismaux/administration et posologie , Canada , Sujet âgé , Facteurs de risque , Dépistage de masse/méthodes , AdulteRÉSUMÉ
During the COVID-19 pandemic, several drugs were repositioned and combined to quickly find a way to mitigate the effects of the infection. However, the adverse effects of these combinations on the gastrointestinal tract are unknown. We aimed investigate whether Hydroxychloroquine (HD), Azithromycin (AZ), and Ivermectin (IV) used in combination for the treatment of COVID-19, can lead to the development of gastrointestinal disorders. This is a systematic review and network meta-analysis conducted using Stata and Revman software, respectively. The protocol was registered with PROSPERO (CRD42023372802). A search of clinical trials in Cochrane Library databases, Embase, Web of Science, Lilacs, PubMed, Scopus and Clinicaltrials.gov conducted on November 26, 2023. The eligibility of the studies was assessed based on PICO criteria, including trials that compared different treatments and control group. The analysis of the quality of the evidence was carried out according to the GRADE. Six trials involving 1,686 COVID-19 patients were included. No trials on the association of HD or AZ with IV met the inclusion criteria, only studies on the association between HD and AZ were included. Nausea, vomiting, diarrhea, abdominal pain and increased transaminases were related. The symptoms of vomiting and nausea were evaluated through a network meta-analysis, while the symptom of abdominal pain was evaluated through a meta-analysis. No significant associations with these symptoms were observed for HD, AZ, or their combination, compared to control. Low heterogeneity and absence of inconsistency in indirect and direct comparisons were noted. Limitations included small sample sizes, varied drug dosages, and potential publication bias during the pandemic peak. This review unveils that there are no associations between gastrointestinal adverse effects and the combined treatment of HD with AZ in the management of COVID-19, as compared to either the use of a control group or the administration of the drugs individually, on the other hand, highlighting the very low or low certainty of evidence for the evaluated outcomes. To accurately conclude the absence of side effects, further high-quality randomized studies are needed.
Sujet(s)
Azithromycine , Traitements médicamenteux de la COVID-19 , Association de médicaments , Maladies gastro-intestinales , Hydroxychloroquine , Méta-analyse en réseau , SARS-CoV-2 , Azithromycine/usage thérapeutique , Azithromycine/effets indésirables , Humains , Hydroxychloroquine/usage thérapeutique , Hydroxychloroquine/effets indésirables , Maladies gastro-intestinales/induit chimiquement , Maladies gastro-intestinales/épidémiologie , COVID-19 , Ivermectine/usage thérapeutique , Ivermectine/effets indésirables , Antibactériens/usage thérapeutique , Antibactériens/effets indésirables , Antiviraux/usage thérapeutique , Antiviraux/effets indésirablesRÉSUMÉ
ABSTRACT: Hydroxychloroquine (HCQ) and chloroquine (CQ) are foundational treatments for several systemic autoimmune rheumatic diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Concerns regarding the risk of cardiac arrhythmia and death have been raised, yet the burden of HCQ and CQ-related cardiac toxicities remains unclear. A systematic literature search was conducted in the MEDLINE and Embase databases for articles published between the earliest date and April 2023 reporting cardiac conduction abnormalities in patients with systemic autoimmune rheumatic diseases taking HCQ or CQ. Meta-analysis was performed to calculate the difference in mean corrected QT (QTc) interval and odds ratio of prolonged QTc interval in those taking HCQ or CQ versus not. Of 2673 unique records, 34 met the inclusion criteria, including 70,609 subjects. Thirty-three studies reported outcomes in HCQ and 9 in CQ. Five studies reported outcomes in RA, 11 in SLE, and 18 in populations with mixed rheumatic diseases. Eleven studies reported mean QTc and OR for prolonged QTc for meta-analysis, all reporting outcomes in HCQ. There was a significant increase in mean QTc (10.29 ms, P = 0.458) among HCQ users compared to non-HCQ users in patients with RA. There was no difference in mean QTc between HCQ and non-HCQ users in other systemic autoimmune rheumatic diseases. When rheumatic diseases were pooled, HCQ users were more likely to have prolonged QTc compared to non-HCQ users (odds ratio 1.57, 95% CI, 1.19, 2.08). The results of this study suggest that clinicians should be aware of potential adverse cardiac events of HCQ and consider QTc monitoring for patients on HCQ for the treatment of systemic autoimmune rheumatic diseases.
Sujet(s)
Antirhumatismaux , Troubles du rythme cardiaque , Maladies auto-immunes , Chloroquine , Mort subite cardiaque , Hydroxychloroquine , Rhumatismes , Hydroxychloroquine/effets indésirables , Humains , Antirhumatismaux/effets indésirables , Troubles du rythme cardiaque/induit chimiquement , Troubles du rythme cardiaque/diagnostic , Troubles du rythme cardiaque/mortalité , Troubles du rythme cardiaque/physiopathologie , Chloroquine/effets indésirables , Rhumatismes/traitement médicamenteux , Rhumatismes/mortalité , Mort subite cardiaque/étiologie , Mort subite cardiaque/épidémiologie , Maladies auto-immunes/induit chimiquement , Maladies auto-immunes/diagnostic , Maladies auto-immunes/mortalité , Maladies auto-immunes/traitement médicamenteux , Appréciation des risques , Mâle , Femelle , Adulte d'âge moyen , Adulte , Facteurs de risque , Cardiotoxicité , Sujet âgé , Rythme cardiaque/effets des médicaments et des substances chimiques , Jeune adulte , Résultat thérapeutique , Potentiels d'action/effets des médicaments et des substances chimiques , Adolescent , Lupus érythémateux disséminé/traitement médicamenteux , Lupus érythémateux disséminé/diagnostic , Lupus érythémateux disséminé/mortalitéRÉSUMÉ
STUDY QUESTION: What are the outcomes of pregnancies exposed to hydroxychloroquine (HCQ) in women with a history of recurrent pregnancy loss (RPL), and what factors predict the course of these pregnancies beyond the first trimester? SUMMARY ANSWER: In our cohort of pregnancies in women with a history of RPL exposed to HCQ early in pregnancy, we found that the only factor determining the success of these pregnancies was the number of previous miscarriages. WHAT IS KNOWN ALREADY: Dysregulation of the maternal immune system plays a role in RPL. HCQ, with its dual immunomodulating and vascular protective effects, is a potential treatment for unexplained RPL. STUDY DESIGN, SIZE, DURATION: The FALCO (Facteurs de récidive précoce des fausses couches) registry is an ongoing French multicenter infertility registry established in 2017 that includes women (aged from 18 to 49 years) with a history of spontaneous RPL (at least three early miscarriages (≤12 weeks of gestation (WG)) recruited from several university hospitals. PARTICIPANTS/MATERIALS, SETTING, METHODS: Spontaneous pregnancies enrolled in the FALCO registry with an exposure to HCQ (before conception or at the start of pregnancy) were included. Pregnancies concomitantly exposed to tumor necrosis factor inhibitors, interleukin-1 and -2 inhibitors, intravenous immunoglobulin, and/or intravenous intralipid infusion, were excluded. Concomitant treatment with low-dose aspirin (LDA), low-molecular weight heparin (LMWH), progesterone, and/or prednisone was allowed. All patients underwent the recommended evaluations for investigating RPL. Those who became pregnant received obstetric care in accordance with French recommendations and were followed prospectively. The main endpoint was the occurrence of a pregnancy continuing beyond 12 WG, and the secondary endpoint was the occurrence of a live birth. MAIN RESULTS AND THE ROLE OF CHANCE: One hundred pregnancies with HCQ exposure in 74 women were assessed. The mean age of the women was 34.2 years, and the median number of previous miscarriages was 5. Concomitant exposure was reported in 78 (78%) pregnancies for prednisone, 56 (56%) pregnancies for LDA, and 41 (41%) pregnancies for LMWH. Sixty-two (62%) pregnancies ended within 12 WG, the other 38 (38%) continuing beyond 12 WG. The risk of experiencing an additional early spontaneous miscarriage increased with the number of previous miscarriages, but not with age. The distributions of anomalies identified in RPL investigations and of exposure to other drugs were similar between pregnancies lasting ≤12 WG and those continuing beyond 12WG. The incidence of pregnancies progressing beyond 12 WG was not higher among pregnancies with at least one positive autoantibody (Ab) (i.e. antinuclear Ab titer ≥1:160, ≥1 positive conventional and/or non-conventional antiphospholipid Ab, and/or positive results for ≥1 antithyroid Ab) without diminished ovarian reserve (18/51, 35.3%) than among those without such autoantibody (18/45, 40.0%) (P = 0.63). Multivariate analysis showed that having ≤4 prior miscarriages was the only factor significantly predictive for achieving a pregnancy > 12 WG, after adjustment for age and duration of HCQ use prior to conception (adjusted odds ratio (OR) = 3.13 [1.31-7.83], P = 0.01). LIMITATIONS, REASONS FOR CAUTION: Our study has limitations, including the absence of a control group, incomplete data for the diagnostic procedure for RPL in some patients, and the unavailability of results from endometrial biopsies, as well as information about paternal age and behavioral factors. Consequently, not all potential confounding factors could be considered. WIDER IMPLICATIONS OF THE FINDINGS: Exposure to HCQ in early pregnancy for women with a history of RPL does not seem to prevent further miscarriages, suggesting limited impact on mechanisms related to the maternal immune system. STUDY FUNDING/COMPETING INTEREST(S): The research received no specific funding, and the authors declare no competing interests. TRIAL REGISTRATION NUMBER: clinicaltrial.gov NCT05557201.
Sujet(s)
Avortements à répétition , Hydroxychloroquine , Enregistrements , Humains , Femelle , Grossesse , Hydroxychloroquine/usage thérapeutique , Hydroxychloroquine/effets indésirables , Adulte , Avortements à répétition/épidémiologie , France/épidémiologie , Études prospectives , Issue de la grossesse , Jeune adulte , Adulte d'âge moyen , AdolescentRÉSUMÉ
Immunosuppressive agents are routinely used to control autoimmunity. However, some adverse events are correlated to their clinical applications. The aim of this study was to study the clinical findings and ocular and cutaneous side effects of chloroquine (CQ) and hydroxychloroquine (HCQ), as current immunomodulators, in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). This descriptive study was performed on 360 individuals referred to the Rheumatology clinic during 2003-2020. Demographic characteristics and other information were collected from patients with RA and SLE. Skin and ocular complications were evaluated in patients who were on treatment with CQ and HCQ. Study populations consisted of 199 subjects with RA and 161 cases with SLE. The frequencies of skin and ocular complications in all patients treated with CQ and HCQ were 32 (17.65%) and 94 (51.9%), respectively. The prevalence of skin complications in patients with RA and SLE was 20 (10.05%) and 22 (13.66%), respectively. The frequencies of ocular complications in patients with RA and SLE were, respectively, 58 (29.4%) and 36 (22.5%). Multiple logistic regression analysis revealed that ophthalmic complications of CQ and HCQ in all patients were dependent on the effects of the duration of drug uses, disease duration, and cumulative doses (p < 0.05), unlike skin complications. Disease types had no effect on ocular complications. Based on these findings, treatment with CQ and HCQ participates in some skin and ocular complications in patients with RA and SLE which are largely associated with the duration of disease and treatment.
Sujet(s)
Polyarthrite rhumatoïde , Chloroquine , Hydroxychloroquine , Lupus érythémateux disséminé , Humains , Hydroxychloroquine/effets indésirables , Hydroxychloroquine/usage thérapeutique , Polyarthrite rhumatoïde/traitement médicamenteux , Lupus érythémateux disséminé/traitement médicamenteux , Chloroquine/effets indésirables , Femelle , Mâle , Adulte d'âge moyen , Adulte , Antirhumatismaux/effets indésirables , Antirhumatismaux/usage thérapeutique , Maladies de l'oeil/induit chimiquement , Maladies de la peau/induit chimiquement , Sujet âgéRÉSUMÉ
Hydroxychloroquine (HCQ) is a disease-modifying anti-rheumatic medication for the treatment of various autoimmune conditions. A rare side effect of HCQ is thrombotic thrombocytopenic purpura (TTP). We present two cases of patients who developed purpura that did not meet TTP criteria following treatment with HCQ. While the etiology of HCQ-associated TTP is poorly understood, we propose a spectrum of manifestations related to HCQ, ranging from benign purpura to TTP. As multiple factors contribute to the disease, we believe that HCQ may act as a "second hit" in patients with genetic susceptibility, which also influences the variability in the severity of disease manifestations. J Drugs Dermatol. 2024;23(5):e124. doi:10.36849/JDD.7781e.
Sujet(s)
Antirhumatismaux , Hydroxychloroquine , Humains , Antirhumatismaux/effets indésirables , Hydroxychloroquine/effets indésirables , Hydroxychloroquine/administration et posologie , Purpura thrombotique thrombocytopénique/induit chimiquement , Purpura thrombotique thrombocytopénique/diagnosticRÉSUMÉ
Phospholipidosis is a rare disorder which consists of an excessive intracellular accumulation of phospholipids and the appearance of zebra bodies or lamellar bodies when looking at them using electron microscopy. This disease is associated with certain genetic diseases or is secondary to drugs or toxins. Drug-induced phospholipidosis encompasses many types of pharmaceuticals, most notably chloroquine, amiodarone or ciprofloxacin. Clinically and histologically, renal involvement can be highly variable, with the diagnosis not being made until the zebra bodies are seen under an electron microscope. These findings may require genetic testing to discount Fabry disease, as its histological findings are indistinguishable. Most of the chemicals responsible are cationic amphiphilic drugs, and several mechanisms have been hypothesized for the formation of zebra bodies and their pathogenic significance. However, the relationship between drug toxicity and phospholipid accumulation, zebra bodies and organ dysfunction remains enigmatic, as do the renal consequences of drug withdrawal. We present, to our knowledge, the first case report of acute renal injury with a monoclonal gammopathy of renal significance, lesions, and sclerodermiform syndrome, with zebra bodies that were associated with the initiation of a hydroxychloroquine and amiodarone treatment, as an example of drug-induced-phospholipidosis.
Sujet(s)
Amiodarone , Hydroxychloroquine , Phospholipides , Humains , Atteinte rénale aigüe/induit chimiquement , Amiodarone/effets indésirables , Hydroxychloroquine/effets indésirables , Hydroxychloroquine/usage thérapeutique , Lipidoses/induit chimiquement , Paraprotéinémies/induit chimiquement , Femelle , Sujet âgéRÉSUMÉ
This text addresses the implications of misinformation during the COVID-19 pandemic, focusing on the use of hydroxychloroquine (HCQ) and other drugs based on a specific publication. The article titled "Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: an estimate," published in 2024 in the journal Biomedicine and Pharmacotherapy, reveals 17 000 deaths associated with the inappropriate use of HCQ in 6 countries, excluding Brazil and India. The dissemination of ineffective drugs, the persistence in recommending HCQ in Brazil, and the lack of an effective response from academia underscore the fragility of public health systems under pressure. Transparent communication between the scientific community and the public is vital, particularly considering studies, such as the one published in Nature Communications in 2021, which warns of the risks of chloroquine. The text highlights the influence of social media in spreading unverified information and emphasizes the need for criminal liability for those contributing to the spread of misinformation. It concludes by underlining the importance of learning from past mistakes to build a more resilient and informed future in the field of public health.
Sujet(s)
Traitements médicamenteux de la COVID-19 , COVID-19 , Hydroxychloroquine , Santé publique , SARS-CoV-2 , Humains , Hydroxychloroquine/usage thérapeutique , Hydroxychloroquine/effets indésirables , COVID-19/épidémiologie , Pandémies , Santé mondiale , Communication , Médias sociauxRÉSUMÉ
Ocular damage in systemic lupus erythematosus (SLE) may cause insidious visual impairment, but its clinical features and the risk of hydroxychloroquine (HCQ)-related complications are still controversial. We performed a meta-analysis to evaluate ocular damage in SLE, the correlation between eye and systemic involvement, and the ocular side effects of treatment. The database PubMed, Embase, and Ovid were used for literature from reception to July, 2023, and the calculation was carried out with R. About 48,693 patients from 66 studies were included. The results indicated that ocular damage in SLE was insidious, appearing in 28 % of patients with no complaints. The most common symptoms and manifestations were dry eye (30 %) and keratoconjunctivitis sicca (26 %). Retinopathy was detected in 10 % of patients and was related to antiphospholipid antibodies (25 % versus 8 %). The proportion of retinopathy also significantly increased in patients with lupus nephropathy or neuropsychiatric systemic lupus erythematosus (risk ratio of 2.29 and 1.95, respectively). HCQ was used in 82 % of patients, of which 4 % suffered from ocular toxicity. HCQ-related retinopathy was dose-dependent. Dosage below 5 mg/kg/d was relatively effective and safe for long-term use, while routine examination was recommended.
Sujet(s)
Antirhumatismaux , Hydroxychloroquine , Lupus érythémateux disséminé , Humains , Hydroxychloroquine/effets indésirables , Hydroxychloroquine/usage thérapeutique , Lupus érythémateux disséminé/traitement médicamenteux , Lupus érythémateux disséminé/complications , Facteurs de risque , Antirhumatismaux/effets indésirables , Antirhumatismaux/usage thérapeutique , Rétinopathies/induit chimiquement , Rétinopathies/diagnostic , Maladies de l'oeil/induit chimiquement , Maladies de l'oeil/étiologieRÉSUMÉ
Importance: The major toxic effect of hydroxychloroquine is retinopathy. Thus, current guidelines recommend limiting the dose and screening annually for retinopathy among all long-term users, but individual patient factors may be associated with retinopathy risk. Objective: To identify risk factors beyond hydroxychloroquine dose and duration of use for hydroxychloroquine retinopathy. Design, Setting, and Participants: This cohort study of 4677 patients in the Kaiser Permanente Northern California integrated health network who initiated hydroxychloroquine, continued treatment, and underwent retinopathy screening after 5 years of use was conducted from July 1, 1997, to December 31, 2020, with up to 15 years of follow-up. Statistical analysis was performed in August 2023. Exposure: Candidate risk factors included age at hydroxychloroquine initiation, sex, race and ethnicity, indications, chronic kidney disease (CKD), liver disease, diabetes, tamoxifen use, and medications that interact with hydroxychloroquine metabolism. Hydroxychloroquine dose was assessed from pharmacy dispensing records. Main Outcome and Measures: Incident hydroxychloroquine retinopathy was adjudicated from masked review of guideline-recommended screening studies and classified as parafoveal or pericentral pattern. Multivariable Cox proportional hazards regression was used to assess potential risk factors for hydroxychloroquine retinopathy within 15 years of initiation. Results: Of 4677 long-term hydroxychloroquine users (mean [SD] age at initiation, 52.4 [14.1] years; 3877 women [82.9%]), 125 patients developed hydroxychloroquine retinopathy within 15 years (102 parafoveal, 23 pericentral). Older age at time of hydroxychloroquine initiation was associated with retinopathy risk, with adjusted hazard ratios (HRs) of 2.48 (95% CI, 1.28-4.78) for those aged 45 to 54 years, 3.82 (95% CI, 2.05-7.14) for those aged 55 to 64 years, and 5.68 (95% CI, 2.99-10.79) for those aged 65 years or older compared with those younger than 45 years. The risk of retinopathy was higher among females than males (HR, 3.83 [95% CI, 1.86-7.89]), among patients with CKD stage 3 or greater (HR, 1.95 [95% CI, 1.25-3.04]), and among individuals with tamoxifen use (HR, 3.43 [95% CI, 1.08-10.89]). The likelihood of pericentral retinopathy was higher among Asian patients (HR, 15.02 [95% CI, 4.82-46.87]) and Black patients (HR, 5.51 [95% CI, 1.22-24.97]) compared with non-Hispanic White patients. Conclusions and Relevance: This study suggests that increasing age, female sex, CKD stage 3 or greater, and tamoxifen use were associated with a higher risk of hydroxychloroquine retinopathy, whereas being younger than 45 years at hydroxychloroquine initiation and male sex were associated with a lower risk. Race and ethnicity were also associated with the pattern of retinopathy. These factors should be incorporated into hydroxychloroquine dosing decisions.